Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: jaison who wrote (392)	12/31/1998 11:43:00 PM
From: Mike McFarland	Respond to of 4474

Hopefully we will now see a rally into January...I cut my losses on Ariad, but retain 1000 shares (and some warrants but I don't like to admit to those). good luck, maybe that was the bottom this past Monday at 1 3/8 when the 100k block went off. --mike

To: jaison who wrote (392)	1/1/1999 5:46:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 4474

Here's the abstract: Regulated Delivery of Therapeutic Proteins After in Vivo Somatic Cell Gene Transfer Xuehai Ye,Victor M. Rivera,Philip Zoltick,Franklin Cerasoli Jr., Michael A. Schnell, Guang-ping Gao,Joseph V. Hughes,Michael Gilman,James M. Wilson * Stable delivery of a therapeutic protein under pharmacologic control was achieved through in vivo somatic gene transfer. This system was based on the expression of two chimeric, human-derived proteins that were reconstituted by rapamycin into a transcription factor complex. A mixture of two adeno-associated virus vectors, one expressing the transcription factor chimeras and one containing erythropoietin (Epo) under the control of a promoter responsive to the transcription factor, was injected into skeletal muscle of immune-competent mice. Administration of rapamycin resulted in 200-fold induction of plasma Epo. Stable engraftment of this humanized system in immune-competent mice was achieved for 6 months with similar results for at least 3 months in a rhesus monkey. X. Ye, P. Zoltick, M. A. Schnell, G.-p. Gao, J. V. Hughes, J. M. Wilson, Institute for Human Gene Therapy and Departments of Molecular and Cellular Engineering and of Medicine, University of Pennsylvania, and the Wistar Institute, Philadelphia, PA 19104, USA. V. M. Rivera, F. Cerasoli Jr., M. Gilman, ARIAD Pharmaceuticals, Cambridge, MA 02139, USA. * To whom correspondence should be addressed. E-mail: wilsonjm@mail.med.upenn.edu